Recent clinical data support the clinical use of oral lavender oil in patients suffering from subsyndromal anxiety. We identified the molecular mechanism of action that will alter the perception of lavender oil as a nonspecific ingredient of aromatherapy to a potent anxiolytic inhibiting voltage dependent calcium channels (VOCCs) as highly selective drug target. In contrast to previous publications where exorbitant high concentrations were used, the effects of lavender oil in behavioral, biochemical, and electrophysiological experiments were investigated in physiological concentrations in the nanomolar range, which correlate to a single dosage of 80 mg/d in humans that was used in clinical trials. We show for the first time that lavender oil bears some similarities with the established anxiolytic pregabalin. Lavender oil inhibits VOCCs in synaptosomes, primary hippocampal neurons and stably overexpressing cell lines in the same range such as pregabalin. Interestingly, Silexan does not primarily bind to P/Q type calcium channels such as pregabalin and does not interact with the binding site of pregabalin, the a2d subunit of VOCCs. Lavender oil reduces non-selectively the calcium influx through several different types of VOCCs such as the N-type, P/Q-type and T-type VOCCs. In the hippocampus, one brain region important for anxiety disorders, we show that inhibition by lavender oil is mainly mediated via N-type and P/Q-type VOCCs. Taken together, we provide a pharmacological and molecular rationale for the clinical use of the oral application of lavender oil in patients suffering from anxiety.
Introduction
Lavender oil (LA) is an important part of our today's aromatherapy to promote ''well-being'' and to reduce distress and ''ill-being''. ''Well-being'' is a psychological construct comprising several domains related to personality including selfacceptance and purpose in life among others [1] . Thus, changes induced by LA might be more directed to improvement of ill-being and distress which show overlap with anxiety and tension at the biological level [2] . When applied by inhalation LA has been associated not only with feelings of pleasantness but also with some improving effects on mood and anxiety [3, 4] . While most if not all of those effects of lavender oil in aromatherapy may be mediated by its pleasant odour there is increasing evidence strongly suggesting a pharmacodynamic effect of LA independent of its odour when applied systemically. I) Anxiolytic properties have been demonstrated for LA in experimental animals following inhalation of very high concentrations but also after i.p. or oral administration [5] [6] [7] [8] . II) When given in capsules containing 100 or 200 ml LA, anxiolytic properties have been shown in human volunteers following stressful situations [9] . III) Recent clinical trials using Silexan, a standardized LA oil preparation, showed pronounced effects in patients with subsyndromal or subthreshold anxiety disorders as well as in patients with Generalized Anxiety Disorder (GAD) after oral administration. Importantly, Silexan was similarly active compared to the benzodiazepine lorazepam (0,5 mg) during 6 weeks of treatment [10] in patients suffering from GAD. Silexan is a patented active substance produced from Lavandula angustifolia flowers by steam distillation consisting of the main active constituents. linalool (36.8%) and linalyl acetate (34.2%). Silexan (active substance of LaseaH, available as immediate release soft gelatine capules containing 80 mg) has been licensed in Germany for the oral treatment of subsyndromal anxiety and tension in 2009.
Even if several preclinical behavioural pharmacological studies and the new clinical data clearly show the anxiolytic activity of LA and especially of Silexan, the molecular mechanism of action explaining these positive effects was missing. In contrast to previous studies, we used physiological relevant concentrations of Silexan which where found in pharmacokinetic experiments. First, we showed anxiolytic effects of Silexan at these low concentrations in behavioural pharmacological tests such as the elevated plus maze. Second, Silexan showed similar effects compared to the established anxiolytics diazepam and pregabalin. To decipher the molecular mechanism of Silexan, we tested whether Silexan modulates the activity of voltage operated calcium channels (VOCCs) since Silexan did not reveal any affinity to known targets of other anxiolytic drugs (SERT, NET, DAT, MAO-A and the GABA A -receptor; data not shown). Under pathological conditions like anxiety or stress disorders, it has been speculated that enhanced Ca 2+ -influx mainly through N and P/Q type VOCCs may increase the release of neurotransmitters such as glutamate and norepinephrine [11, 12] which are involved in the pathogenesis of these diseases. Third, we show for the first time that Silexan unselectively inhibits several VOCCs, such as P/Q-type and Ntype VOCCs using a broad set of methods including calcium imaging as well as patch clamp technique. In addition, we were able to demonstrate that Silexan does not bind to the binding site of pregabalin at the P/Q type calcium channels. Pregabalin modulates P/Q type VOCCs after binding at the auxiliary a2d-1 or -2 subunits and thereby reduces Ca 2+ -influx through these channels [13, 14] . Taken together, we elucidate the anxiolytic mechanism of action of LA and thereby provide a molecular rationale for the clinical use of Silexan.
Materials and Methods

Animals
Female 2-3 months old NMRI mice with an average weight of 30 g were used for the preparation of synaptosomes, purified synaptosomal membranes and for the determination of pentobarbital sleep time. Male 2-3 months old NMRI mice were utilized for the elevated plus maze test. For the preparation of primary hippocampal neurons female time-mated Sprague-Dawley rats were used. Animals were purchased from Charles River Laboratories, Sulzfeld, Germany or Janvier SAS, St. Berthevin, France. All animal care and experimental procedures were in concordance with the German law on animal care and handling of animals and the guidance of the European Community Council Directive, and the protocol was approved by the local commission for the Care 
Pentobarbital sleep time
Female NMRI mice were treated orally for 9 days with dosages between 1 and 30 mg/kg Silexan, 0.2% agar suspension (10 ml/ kg) or pregabalin (100 mg/kg). Pentobarbital (45 mg/kg) was diluted in physiological saline and administered i.p. to each mouse one hour after last treatment. The sleeping time was defined as the lapse of time required to change from dorsal position to the normal position.
Isolation and plating of rat P0-P2 hippocampal neurons
Primary hippocampal neurons were prepared from P0-P2 Sprague-Dawley rat pups according to Amaral et al using the Worthington Papain Dissociation Kit (Worthington, Lakewood, NJ) [15] . Cells were plated on poly-D-lysine/laminin coated glass cover slips in serum free Neurobasal A media containing Lglutamine (1 mM) and 2% B27 in 6 well plates at a density of 2610 5 cells per well. Neurons were grown in 37uC in a humidified incubator containing 5% CO 2 in air. Cultures were maintained for 14 days before experimental procedures.
Calcium measurements in primary hippocampal neurons
Intracellular Ca 2+ measurements were conducted according to literature [16, 17] . After 14 days, hippocampal neurons on cover slips were loaded with 1 mM fura-2-AM for 30 min and then placed on the stage of an inverted Axiovert S100 microscope (Zeiss, Oberkirchen, Germany). Intracellular calcium concentrations were measured by dual excitation (340/380 nm) ratio method.
Synaptosomal preparations for intracellular calcium measurements
Murine synaptosomes from whole brain without cerebellum were prepared as described previously [18] . Synaptosomal samples were loaded with 5 mM fura-2-AM for 40 min. Fura-2-signals were calibrated according to the method of Grynkiewicz et al, using a K D value of 224 nM [19] . For the determination of R max and R min 0,2% sodium dodecyl sulphate and tris(hydroxymethyl) aminomethane (Tris) 30 mM/ethylene glycol bis(2-aminoethyl ether)-N,N,N9N9-tetraacetic acid (EGTA) 6 mM, respectively were added.
[ 3 H]-gabapentin binding studies
Partially purified synaptic membranes were prepared from mouse cortex using sucrose density gradients according to SumanChauhan et al [20] . Protein content of synaptic membrane suspension was determined by the Lowry protein assay [21] . For 3 H]-gabapentin in 10 mM HEPES buffer (pH 7.4 at RT) in the presence of varying concentrations of test compound for 40 min. Afterwards, the samples were filtered through Whatman GF/B filters under vacuum. Filters were washed 3 times with 5 ml ice-cold 100 mM NaCl. Bound radioactivity was determined using liquid scintillation counting. Non-specific binding was defined by 1 mM pregabalin.
Electrophysiological recordings
For measurement of N-and P/Q-type currents, different transfected cell lines were applied, each expressing only one VOCC subtype. N-type channel recordings were carried out on CHO cells stably expressing Cav2.2, a2d-1 and b-subunits. The cell line was kindly provided by B. Fakler, Institute of Physiology II, University of Freiburg, Germany. Cells were grown in Minimal Essential Medium (MEM) ALPHA including 10% fetal calf serum, L-glutamine 200 mM, G418 0.7 mg/ml, hygromycin B 0.25 mg/ ml and blasticidin 5 mg/ml. For P/Q-type current analysis, HEK 293 cells were transiently transfected with a2d-1 and b3a subunits, as previously described, whereas the a 1A subunit was cloned in a pEGFP-N1 vector [22] .
Whole cell calcium currents were recorded using the HEKA-10 patch clamp amplifier (HEKA Electronic, Lambrecht, Germany). For measurement of calcium current inhibition by Silexan, extracellular solution containing vehicle or Silexan was applied by superfusion and currents were recorded at 1 Hz during a 50 ms depolarizing pulse to 20 mV. The extracellular solution contained (in mM): CaCl 2 10, tetraethylammonium chloride (TEA-Cl) 125, HEPES 10 and glucose 5. The pH was adjusted to 7.4 using TEA-OH. The intracellular solution contained (in mM): CsCl 110, HEPES 10, EGTA 10, MgCl 2 3, Na-adenosine triphosphate (Na-ATP) 3 and guanosine 5-triphosphate tris salt (GTP-Tris) 0.6. The pH was adjusted to 7.2 using CsOH. Patch pipettes were pulled from borosilicate glass tubing (Sutter Instruments, Novato, CA, USA) with input resistance ranged between 1.8 and 4.0 MV. Cell capacitance ranged between 12 and 25 pF for N-type cells and 10 and 50 pF for P/Q-type cells. Series resistance was typically between 2.5 and 8 MV and was compensated up to 70%. Data were recorded with HEKA pulse 8.5 software package and analysed off-line. The holding potential in experiments with N-or P/Q-type cells was 280 mV.
Statistical analysis
Results were expressed as mean 6 SEM. Statistical analyses were performed with two-sided t-tests. Stars represent p-values: ***p,0.001, **p,0.01, *p,0.05.
Results
Silexan improves anxiolytic behaviour in the elevated plus maze test
Several groups previously showed anxiolytic effects of LA preparations given by inhalation not standardized concerning their composition [6, 7] . None of these studies dealt with anxiolytic effects of oral administered LA in dosages which are in accordance with the dosage of 80 mg/d used in humans. Therefore, we tested the anxiolytic activity of Silexan in the elevated plus maze test, a well established anxiety model. Mice were treated orally for 3 days with Silexan, the benzodiazepine diazepam or the gabapentinoid (Fig. 1A) . This anxiolytic effect is dose-dependent and already maximal at a concentration of 3 mg/kg BW. Similar to diazepam and pregabalin, Silexan also elevated the pentobarbital sleeping time (Fig. 1D ) at similar concentrations (3-30 mg/kg) in accordance with Linck et al [8] . As Silexan does not show sedation in humans, this finding rather suggests sleep promoting than sedative properties [9, 10, [23] [24] [25] [26] .
Similar effects of Silexan and pregabalin on VOCCs in murine synaptosomes
Silexan showed no affinity to known targets of other anxiolytic drugs such as SERT, NET, DAT, MAO-A and the GABA Areceptor (data not shown). Therefore, we investigated if Silexan shares its mode of action with the gabapentinoid pregabalin which targets the a2d-1 and -2 subunits of VOCCs. We examined, if Silexan and pregabalin inhibit Ca 2+ -influx in murine synaptosomes ( Fig. 2A-C ). VOCCs were activated by KCl. Under these conditions pregabalin inhibited Ca 2+ -influx substantially ( Fig. 2A,  2C ). Maximal effects were already seen at a concentration of 3 mM reducing the Ca 2+ -influx to 65.8666.71%. Increasing pregabalin concentrations did not show any additional effect. Silexan dosedependently reduced KCl-induced Ca 2+ -increase in a biphasic mode, showing an inhibition of about 20% at concentrations between 0.1 and 1 mg/ml (Fig. 2B, 2C ). Contrary to pregabalin, Silexan further decreased Ca 2+ -elevation at higher concentrations, exceeding pharmacologically relevant plasma levels in man and animal by several orders of magnitude (data not shown). The major ingredients of Silexan are linalool and linalyl acetate which each make up to about 35% of the product. However, linalool and linalyl acetate are similarly active when applied directly to the synaptosomes (Fig. 2E) . Due to the fact that linalyl acetate is completely metabolized to linalool, we estimated an IC 50 value for linalool of about 37 nM (Fig. 2D) .
One possible explanation for this effect could be a nonspecific modulation of channels properties by alterations of membrane fluidity. However, using the fluorescence probe 1,6-diphenyl-1,3,5-hexatriene and mouse brain membranes according to Kirsch et al. [27] , no effect of Silexan on membrane fluidity was seem up to concentrations of 100 mg/ml. To further investigate if the Silexan and linalool mediated effects on VOCCs are selective, we additionally investigated several terpenes with closely related chemical structures such as geraniol, cineol and dihydrolinalool. Importantly, none of the other terpenes inhibited KCl induced calcium influx (Fig. 2F) supporting the idea that this effect is specific for linalool and lavender oil and is not a common phenomenon of lipophilic monoterpenes.
Silexan also inhibits VOCCs in primary hippocampal neurons
To further characterize the effects of Silexan on VOCCs, we decided to study KCl dependent Ca 2+ -influx in primary hippocampal neurons because of the important role of the hippocampus for regulating emotions and anxiety. Similar to the effects obtained in synaptosomes, Silexan inhibited significantly and dose-dependently KCl induced Ca 2+ -increase (Fig. 3A, C Fig.3B, C, E, H) .
Silexan does not bind to the gabapentin binding site at a 2 d-subunits of P/Q-type VOCCs
The specific effects of pregabalin and the structurally related drug gabapentin on presynaptic VOCCs of the P/Q-type have been associated with the specific binding to the modulating and partially extracellularly located subunit a2d-1 and -2, which can be labelled by [ 3 H]-gabapentin binding [13, 28] . In agreement with the literature pregabalin inhibited specific [ (Fig. 4A) [29] . In contrast, no effect on [ 3 H]-gabapentin binding was observed for Silexan (Fig. 4B) . Thus, even if both drugs seem to interact with VOCCs, they probably do not share the same binding site at VOCCs. 
G i coupled G-protein receptors are not involved in VOCCs inhibition by Silexan
Modulation of VOCCs could either occur via direct action on the VOCC protein complex or indirect via activation of upstream G i coupled receptors, e.g. cannabinoid receptors [30] . We measured KCl-induced Ca 2+ -elevation in primary hippocampal neurons treated with Silexan in the presence or absence of pertussis toxin (PTX). PTX specifically and irreversibly inactivates G i protein coupled receptors via catalysis of G ai subunit ADPribosylation [31] . Silexan reduced significantly depolarisation induced Ca 2+ -influx independent of PTX treatment (Fig. 4C) . Arachidonylethanolamide was used as positive control. The endogenous ligand for the CB 1 cannabinoid receptor decreased KCl-induced Ca 2+ -influx to 44.2669.37% [32] . Due to G i protein involvement, the inhibitory effect was almost completely abolished after PTX treatment (91.28616.22%). Taken together, Silexan does not interact with G i coupled G-protein coupled receptors.
Silexan inhibits different classes of VOCCs
To elucidate if Silexan preferentially inhibits P/Q type VOCCs such as pregabalin, we deternined the effects of Silexan in the presence of the P/Q type inhibitor v-agatoxin IVA and the Ntype inhibitor v-conotoxin GVIA because these two channel types mainly promote the KCl mediated Ca2+-increase in primary hippocampal and in synaptosomes (please also see Supplementary Figure S1 ).
Both toxins used in this study target ligand-binding pockets at the a 1 subunit and have been reported to act additively [33, 34] . This was confirmed in our experiments. After single toxin incubation, v-agatoxin IVA reduced KCl-induced Ca 2+ -elevation to 65.0268.88%, while v-conotoxin GVIA diminished Ca 2+ -currents to 68.4463.16%. Joint application of the two toxins lowered KCl-evoked increase in intrasynaptosomal Ca 2+ -concentrations to 40.4363.55% (Fig. 4D) . To test if Silexan acts specifically at a single VOCC subtype, we performed combined application measurements with v-conotoxin GVIA (30 nM; Fig. 4E ) or v-agatoxin IVA (100 nM; Fig. 4F ). When both toxins were applied together with Silexan, no relevant additive effects were observed. This observation strongly argues against a specific effect of Silexan at one of the individual VOCCs.
This last observation prompted us to further investigate the effects of Silexan on the properties of VOCCs using the patchclamp technique. In CHO cells stably expressing N-type VOCC, Silexan displayed a concentration-dependent inhibition of Ca 2+ currents (Fig. 5A/C/D) . Silexan 1 mg/ml already reduced Ca 2+ currents significantly by about 10%. At the higher concentration of 10 mg/ml Ca 2+ currents were additionally inhibited to about 80%. The currents recover after washing out Silexan 1 mg/ml and -influx in murine synaptosomes. Synaptosomes were preincubated with v-agatoxin IVA (100 nM), v-conotoxin GVIA (30 nM) or a combination of both inhibitors for 10 min. Afterwards, they were stimulated with KCl (80 mM). Silexan (1 mg/ml) causes no significant additive effects when combined with the N-type VOCCs inhibitor v-conotoxin GVIA (30 nM, E), or the P/Q-type inhibitor v-agatoxin IVA (100 nM, F; n = 9-12). All data presented are mean values 6 SEM (paired t-test). doi:10.1371/journal.pone.0059998.g004 10 mg/ml (Fig. 5 E,F) . Silexan also affected other VOCCs. This could be demonstrated in transiently transfected HEK 293 cells, expressing the P/Q-type channel (Fig. 5B) . Silexan caused a reduction of Ca 2+ currents in P/Q-type expressing cells to a similar extent and in a similar dose-dependent fashion. Electrophysiological recordings in HEK 293 cells stably expressing the Ttype VOCC revealed that Silexan also inhibits low voltage activated currents at this channel (data not shown). Taken together, our findings suggest that Silexan acts non-specifically at different classes of VOCC.
Discussion
In the past, several mechanisms for lavender oil's beneficial effects on anxiety and mood were postulated, including interactions with NMDA or GABA A receptors, voltage dependent sodium channels, or glutamatergic and cholinergic neurotrans- . (E and F) Time course of the N-type Ca2+ channel peak current amplitude for 125 seconds by depolarizing pulses to +20 mV at a pulse frequency of 1 Hz. Inhibition of the N-type Ca2+ channel peak current amplitude by Silexan 1 mg/ml (E) or 10 mg/ml (F) compared to DMSO. The arrows indicate the time points of the Silexan application and the washout. A total number of 10 (DMSO), 14 (Silexan 1 mg/ml) and 9 cells (Silexan 10 mg/ml) were averaged. All data presented are mean values 6 SEM (unpaired t-test). doi:10.1371/journal.pone.0059998.g005 mission [35] [36] [37] [38] [39] . Most of these effects were observed in the millimolar or high micromolar concentration range.
Here we show three novel findings. First, Silexan shows anxiolytic effects in the elevated plus maze test at low oral doses (1-10 mg/kg BW) corresponding to dosages given in humans (80 mg/d). Second, our studies revealed an inhibition of VOCCs by Silexan at nanomolar concentrations. Third, pregabalin and Silexan do not share the molecular target, the a2d subunit of P/Q type channels [13, 40] . In addition, Silexan did not inhibit Ca 2+ -increase via VOCCs as a consequence of previous activation of G i coupled receptors. Silexan unselectively modulates with similar potency several VOCCs such as the N-type and the P/Q type VOCCs. This parallels to some extent pregabalin, which acts on the VOCC channel complex via the a2d subunit but mainly inhibits P/Q type calcium channels. The precise mechanisms of the channel modulation by Silexan are not yet known but may be either direct by binding and inhibiting the channel complex or more indirect by influencing the properties or surface expression of VOCC subunits.
Taken together, we shed light into the molecular mechanism of action of LA in anxiety and thereby might help to further establish the clinical use of Silexan in patients suffering from anxiety. Author Contributions
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